118 related articles for article (PubMed ID: 2702978)
1. Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro.
Samadi-Baboli M; Favre G; Blancy E; Soula G
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):233-41. PubMed ID: 2702978
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug--LDL complex via the LDL receptor pathway in vitro.
Samadi-Baboli M; Favre G; Bernadou J; Berg D; Soula G
Biochem Pharmacol; 1990 Jul; 40(2):203-12. PubMed ID: 2375762
[TBL] [Abstract][Full Text] [Related]
3. [Targeting of tumor cells by low density lipoproteins: principle and use of ellipticin derivatives].
Favre G
C R Seances Soc Biol Fil; 1992; 186(1-2):73-87. PubMed ID: 1450992
[TBL] [Abstract][Full Text] [Related]
4. Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.
Samadi-Baboli M; Favre G; Canal P; Soula G
Br J Cancer; 1993 Aug; 68(2):319-26. PubMed ID: 8347487
[TBL] [Abstract][Full Text] [Related]
5. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway.
Lundberg B
Cancer Res; 1987 Aug; 47(15):4105-8. PubMed ID: 3607752
[TBL] [Abstract][Full Text] [Related]
6. 3'-Hydroxyesorubicin. Synthesis and antitumor activity.
Priebe W; Neamati N; Perez-Soler R
J Antibiot (Tokyo); 1990 Jul; 43(7):838-46. PubMed ID: 2387778
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of uptake and cytotoxicity of a low-density lipoprotein-daunomycin complex in P388 leukemic cells.
Yanovich S; Preston L; Shaw JM
Cancer Res; 1984 Aug; 44(8):3377-82. PubMed ID: 6744272
[TBL] [Abstract][Full Text] [Related]
8. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
Sladek NE; Landkamer GJ
Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
[TBL] [Abstract][Full Text] [Related]
9. Effect of 3'-amino-3'-deoxythymidine on L1210 and P388 leukemias in mice.
Lin TS; Fischer PH; Prusoff WH
Biochem Pharmacol; 1982 Jan; 31(1):125-8. PubMed ID: 7059345
[No Abstract] [Full Text] [Related]
10. Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias.
Cholody WM; Martelli S; Konopa J
J Med Chem; 1992 Jan; 35(2):378-82. PubMed ID: 1732555
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antitumoral activity of free, and encapsulated taxol.
Bartoli MH; Boitard M; Fessi H; Beriel H; Devissaguet JP; Picot F; Puisieux F
J Microencapsul; 1990; 7(2):191-7. PubMed ID: 1970357
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.
Berners-Price SJ; Mirabelli CK; Johnson RK; Mattern MR; McCabe FL; Faucette LF; Sung CM; Mong SM; Sadler PJ; Crooke ST
Cancer Res; 1986 Nov; 46(11):5486-93. PubMed ID: 3756897
[TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
Jurd L; Narayanan VL; Paull KD
J Med Chem; 1987 Oct; 30(10):1752-6. PubMed ID: 2821258
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HCl.
Auclair C; Pierre A; Voisin E; Pepin O; Cros S; Colas C; Saucier JM; Verschuere B; Gros P; Paoletti C
Cancer Res; 1987 Dec; 47(23):6254-61. PubMed ID: 3677074
[TBL] [Abstract][Full Text] [Related]
15. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells.
Kader A; Pater A
J Control Release; 2002 Apr; 80(1-3):29-44. PubMed ID: 11943385
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor cell growth in vitro and in vivo by 2-methyl 9-hydroxyellipticinium entrapped within phospholipid vesicles.
Sautereau AM; Cros S; Tocanne JF
Biopharm Drug Dispos; 1986; 7(4):357-71. PubMed ID: 3768491
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of 9-hydroxyellipticine (NSC 210717) ON L1210 mouse leukemia and the effect of route of injection.
Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Cros S; Paoletti C
Cancer Res; 1976 Sep; 36(9 pt.1):3067-76. PubMed ID: 975074
[TBL] [Abstract][Full Text] [Related]
18. Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex.
Vitols S; Söderberg-Reid K; Masquelier M; Sjöström B; Peterson C
Br J Cancer; 1990 Nov; 62(5):724-9. PubMed ID: 2245164
[TBL] [Abstract][Full Text] [Related]
19. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
McGovren JP
Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro studies of Tiazofurin and a selenazole analog.
Streeter DG; Robins RK
Biochem Biophys Res Commun; 1983 Sep; 115(2):544-50. PubMed ID: 6138036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
